415 Capital
Venture capitalSan Francisco · Series A–Late Stage · 11 people tracked
Investment thesis
415 Capital invests in medical device companies addressing large unmet patient needs in chronic diseases, with particular focus on cardio and neurovascular disorders—the leading causes of death globally and major healthcare cost drivers. The firm supports entrepreneurs from clinical through commercial stages, leveraging 30+ years of industry expertise and a €2 billion commercial distribution channel across Europe to create patient value while reducing long-term healthcare costs. Portfolio focus includes structural heart disease, heart failure, vascular disease, stroke prevention, hypertension, neuromodulation, imaging, robotics, and patient monitoring technologies.
Source: firm website, verified Jul 21, 2026.
Team · 11 people
from the firm's websiteInvestments · 33 tracked
founders shown can be your intro pathFrequently asked questions
- What stage does 415 Capital invest at?
- 415 Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
- What is 415 Capital's typical check size?
- 415 Capital typically writes checks of $5.7M – $17.1M.
- What sectors does 415 Capital focus on?
- 415 Capital focuses on Healthtech, Medical Devices.
- Where is 415 Capital located?
- 415 Capital is headquartered in San Francisco.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
EQT Life Sciences is one of Europe's largest and most experienced life sciences investors, focusing on innovative companies developing therapeutics, medical devices, diagnostics, and healthtech globally. The firm has raised approximately 3.5 billion euros across 12 private funds and 3 investment strategies over its 30-year history.
USVP is a venture capital firm with over 40 years of history across four generations of technology investing. The firm has deployed $4.7B across 542 companies, generating 97 IPOs, and combines 150 years of combined operating experience with deep expertise in enterprise software, security, consumer technology, and healthcare.